PEX PharmaSequence monthly report - December 2017 Total open market (sell-out report)

Transcription

1 Total open market (sell-out report) Change in comparison to Cumulative YTD Annual sales January 2015 Total turnover (PLN million) Total open market ,1% -6,0% -3,4% ,0% ,0% 10,4% Rx reimbursed ,3% 1,4% -1,6% ,5% ,5% 3,9% Rx nonreimbursed ,4% -8,5% -6,3% ,2% ,2% 10,0% Non Rx products ,2% -9,7% -3,4% ,7% ,7% 17,2% Reimbursement Reimbursement value (PLN million) 702-1,3% 1,6% -1,6% ,5% ,5% 7,2% Reimbursement share In total turnover 24,7% -4,2% 8,2% 1,8% 25,5% 0,5% 25,5% 0,5% -3,0% Reimbursement share In reimbursed sales 69,7% -3,3% 0,9% -0,1% 71,1% 3,2% 71,1% 3,2% 3,5% Average price per pack (PLN) Total 1 19,0 0,4% 10,5% 8,2% 18,4 4,4% 18,4 4,4% 7,7% For reimbursed Rx products 2 27,7 1,9% 3,4% 2,3% 27,4 0,9% 27,4 0,9% -0,2% For nonreimbursed Rx products 3 25,1 0,3% 8,1% 7,5% 24,6 6,2% 24,6 6,2% 10,1% For Non Rx products 4 13,9 2,5% 10,3% 9,8% 13,0 5,9% 13,0 5,9% 12,5% Average mark-up Total 1 24,7% -0,6% -5,1% -2,3% 25,2% -0,9% 25,2% -0,9% -2,1% For reimbursed Rx products 2 18,5% 1,5% -2,9% -2,9% 18,5% -1,2% 18,5% -1,2% 3,5% For nonreimbursed Rx products 3 24,4% 0,1% -2,6% -2,1% 24,8% -1,9% 24,8% -1,9% -9,1% For Non Rx products 4 28,6% -1,8% -3,8% -2,4% 29,4% -1,3% 29,4% -1,3% -5,1% Average pharmacy Number of patients in pharmacies ,1% -14,0% -7,8% ,1% ,1% 3,4% Total turnover (PLN thousand) ,0% -7,2% -4,6% ,8% ,8% 6,5% Total - Total pharmacy turnover cumulative in PLN million - Pharmacy market total 1 Rx reimbursed prescriptions 2 Rx nonreimbursed prescriptions 3 Non Rx products 4 Zmiana vs Total Total January ,8% 982 9,3% ,8% ,5% February ,7% ,2% ,3% ,4% March ,4% ,5% ,5% ,8% April ,8% ,7% ,2% ,7% May ,6% ,8% ,4% ,9% June ,2% ,4% ,3% ,9% July ,0% ,3% ,4% ,4% August ,7% ,4% ,3% ,7% September ,2% ,6% ,8% ,5% October ,8% ,6% ,9% ,3% ,7% ,8% ,1% ,8% ,0% ,5% ,2% ,7% Total Retail sales in PLN.

2 2 Trends - Total monthly pharmacy sales in PLN million Total monthly sales in an average pharmacy in PLN - Retail sales in PLN

3 3 Total turnover (thousand PLN) Average pharmacy YTD' Change Change YTD' Change Value % Value % Value % Total open market ,0% ,6% ,8% Rx reimbursed ,2% ,9% ,3% Rx nonreimbursed ,5% ,5% ,1% Non Rx products ,1% ,6% ,5% Average price per pack (PLN) Total 1 19,0 18,4 18,9 0,1 0,4% 17,6 1 7,4% 17,6 0,8 4,4% For reimbursed Rx products 2 27,7 27,4 27,2 0,5 1,9% 27,1 1 1,6% 27,2 0,3 0,9% For nonreimbursed products 3 25,1 24,6 25,0 0,1 0,3% 23,3 2 6,2% 23,2 1,4 6,2% For Non Rx products 4 13,9 13,0 13,6 0,3 2,5% 12,7 1 8,7% 12,3 0,7 5,9% Average mark-up* Total 1 24,7% 25,2% 24,8% -0,1% -0,6% 25,3% -0,6% 7,4% 25,4% -0,2% -0,8% For reimbursed Rx products 2 18,5% 18,5% 18,2% 0,3% 1,5% 19,0% -0,6% 1,6% 18,7% -0,2% -1,1% For nonreimbursed Rx products 3 24,4% 24,8% 24,4% 0,0% 0,1% 24,9% -0,5% 6,2% 25,3% -0,4% -1,7% For Non Rx products 4 28,6% 29,5% 29,1% -0,5% -1,8% 29,3% -0,7% 8,7% 29,8% -0,4% -1,2% Number of patients Total ,1% ,0% ,1% For reimbursed Rx products ,4% ,4% ,8% For nonreimbursed Rx products ,9% ,6% ,2% For Non Rx products ,7% ,4% ,7% Number of pharmacies - summary ,1% ,2% ,1% *Values in Change value for average mark-up in percentage points - Pharmacies on the open market - Retail sales in PLN

4 4 Companies with the highest retail sales Companies with best sales of Rx products Sales value 1 Sales value change vs Sales volume Sales volume change vs 1 POLPHARMA ,8% -7,6% ,9% -9,5% 2 TEVA ,2% -7,2% ,9% -11,0% 3 SANOFI ,4% -13,5% ,0% -11,3% 4 ADAMED ,2% -0,7% ,5% -3,4% 5 KRKA ,8% -1,8% ,7% -4,2% 6 BAYER ,3% 9,2% ,3% -2,1% 7 SANDOZ ,3% -8,5% ,4% -9,8% 8 GLAXOSMITHKLINE ,5% -7,0% ,9% -8,0% 9 BOEHRINGER INGELHEIM ,1% -1,6% ,5% -3,8% 10 VALEANT ,1% -12,7% ,4% -12,5% 11 MYLAN ,9% -2,0% ,5% -7,0% 12 SERVIER ,7% 1,3% ,8% -1,8% 13 NOVO NORDISK ,6% -8,3% ,2% -8,1% 14 NOVARTIS ,6% -0,1% ,3% -12,4% 15 BERLIN-CHEMIE / MENARINI ,6% 10,2% ,0% 6,3% 16 ASTELLAS ,0% -1,0% ,1% -17,0% 17 GEDEON RICHTER ,3% -3,9% ,9% -6,7% 18 MSD ,1% 1,1% ,5% -11,2% 19 EGIS ,4% -4,6% ,6% -2,8% 20 PFIZER ,3% -9,3% ,1% -15,1% Companies with best sales of Non Rx products - The highest sales of Rx drugs in PLN - - The highest sales of non-prescription products in PLN - Sales value 1 Sales value change vs Sales volume Sales volume change vs 1 AFLOFARM ,0% -2,9% ,7% -5,5% 2 USP ZDROWIE ,2% -10,1% ,8% -14,5% 3 POLPHARMA ,8% 1,1% ,4% -8,4% 4 GLAXOSMITHKLINE ,5% -3,2% ,7% -6,3% 5 TEVA ,2% -11,5% ,1% -15,3% 6 SANOFI ,5% -6,0% ,4% -7,8% 7 HASCO - LEK ,9% 2,7% ,7% -2,3% 8 BAYER ,8% -0,2% ,7% -6,5% 9 VALEANT ,1% -9,9% ,8% -11,8% 10 RECKITT BENCKISER ,6% -8,4% ,1% -9,3% 11 BERLIN-CHEMIE / MENARINI ,2% -11,4% ,8% -14,9% 12 ANGELINI ,6% -3,9% ,2% -5,3% 13 SANDOZ ,9% 16,8% ,5% 18,2% 14 MERCK ,3% 0,6% ,6% -2,6% 15 JOHNSON & JOHNSON ,9% -4,6% ,6% -14,0% 16 HERBAPOL WROCŁAW ,4% 4,9% ,1% -0,8% 17 TAKEDA ,4% -26,6% ,9% -26,8% 18 N.P.ZDROVIT ,6% 6,3% ,5% 3,7% 19 ADAMED ,9% 6,7% ,1% 11,9% 20 OLIMP LAB ,2% -14,0% ,1% -12,1% Any comparisons to previous periods are prepared based on current assignment of products to companies. Data includes food supplements and foodstuffs for particular nutritional use. Data does not include herbs, homeopathic products and cosmetics. Retail sales in PLN.

5 5 Price - Structure of the average retail price - All amounts are retail open pharmacy sales in PLN Most important terms: 1 Total open pharmacy market sales 2 Total sales of Rx products covered by NHF reimbursement 3 Total sales of Rx products not covered by NHF reimbursement 4 Total sales of products available without prescription, including OTC medicines, food supplements, herbs, patches, medical devices, etc.

6 6 PEX PharmaSequence commentary Combined sales of the pharmacy market in reached m PLN, 4% more than in. Reimbursement was 8 419m PLN, a growth of 4,5% compared to. The pharmacy market in saw sales reach more than 2 839m PLN. Value of sales compared to fell by close to 98,5m PLN (-3,4%). Compared to of sales grew by close to 86m PLN (+3,1%). Compared to the same period of, the non-prescription segment fell by 44,02m PLN (-3,4%). Sales based on non-reimbursed prescriptions fell by 39,01m (-6,3%) and on reimbursed prescription by 16,68m PLN (-1,6%). Compared to the previous month, segment value was varied. Value of products sold without a prescription grew by 105,47m PLN (+9,2%), value of reimbursed prescriptions was higher by 22,41m PLN (+2,3%) and of nonreimbursed drugs fell by 39,25 PLN (-6,4%). Average pharmacy mark-up for all drugs in was 24,68% and was smaller by 0,58pp than the margin in the same period of. Compared to of the average pharmacy margin fell by 0,6% (-0,14pp.). The average drug price in was 19,02 PLN and was 0,4% larger than in the previous month, and 8,2% higher than the average price in of. The increase in prices can result from a drop in demand, the pharmacy market is shrinking in compared to in value and volume, whereas product prices for pharmacies are growing. In this context the increase in prices can be seen as a natural process aimed at reducing losses in the mark-up. Drug reimbursement by the National Health Fund in was in the amount of over 702m PLN, 1,6% less than in the same period of. The level of patient copayment for reimbursed drugs in was 29,47%, smaller by 0,01 pp. compared to. Patient copayment for reimbursed drugs grew by 2,55 pp from. - Monthly turnover value forecast (PLN million, retail gross prices) -

7 7 About us PEX PharmaSequence is a Polish consulting and research company with its own wide-ranging resources of market data. We specialise in services for entities operating in the broadly defined healthcare market. As a result of numerous projects, carried out over almost 20 years of the company s operations on the Polish market, for innovative, generic, and OTC producers, PEX PharmaSequence has gained unique expertise that allows us to provide our Clients with valuable support. Knowledge Data Consulting Research Expertise It is not without significance that our team, comprising 60+ people, has the benefit of experience gained in service companies specialising in the pharma sector, as well as industry experience acquired in local and global pharmaceutical companies. Our expertise and competencies as well as our knowledge of the Polish pharma market enable us to develop proposals and efficiently carry out projects, which offer added value to our Clients business decisions. We would like to hear from you! more info Ask us a question: rozwiazania@pexps.pl Krzysztof Gersz Partner, Sales Director, Consulting, Analytics and Market Research Business Unit krzysztof.gersz@pexps.pl Jakub Dalach Partner, Director, Sales, Market Monitoring Department jakub.dalach@pexps.pl Published on the 12th of January 2018, prepared by Błażej Górniak, Marketing Specialist.

8 8 This document has been prepared by PEX PharmaSequence Sp. z o.o. PEX PharmaSequence Sp. z o. o. is not responsible for any potential decisions taken on the basis of this study or their consequences. This document is copyright protected by PEX PharmaSequence Sp. z o.o. It is intended for internal client (buyer) use only. The client has no right to transfer this paper or make it available to third parties (including publication). The client also has no right to disclose this document or any of the data or information which results from it. The aforementioned concerns both the entire document and any part of it. Citing or quoting (fair use) of this document, any part of it or any data resulting from it, is permitted only with written permission from PEX PharmaSequence Sp. z o.o., which outlines the goal and extent of the quotations. PEX PharmaSequence Sp. z o.o. tel.: (+48) fax (+48) biuro@pexps.pl